ArticleAmerican journal of hematology2025
Impact of Cytogenetic Response to Therapy on Long-Term Survival in Acute Myeloid Leukemia.
Article in American journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clonal Cytogenetic Evolution in Relapse of Myeloid Hematological Neoplasms After Allogeneic Stem Cell Transplantation.Cancers · 2026Article
- Impact of Cytogenetic Response to Therapy on Long-Term Survival in Acute Myeloid Leukemia.American journal of hematology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prognostication in acute myeloid leukemia (AML) relies on clinical, molecular, and cytogenetic factors. In this retrospective study, we examined the impact of different levels of cytogenetic response on overall survival (OS) and event-free survival (EFS) in AML. Among 973 adult AML patients treated at Cleveland Clinic (5/2017-9/2023), 563 patients had baseline cytogenetic data and post-treatment response assessment available. Based on baseline and response cytogenetic status, patients were categorized into: normal to normal (NL-Cy to NL-Cy, n = 221, 39%), normal or abnormal to gain (NL/Abnl-Cy to Gain-Cy, n = 46, 8.2%), abnormal to persistent (Abnl-Cy to Persistent-Cy, n = 81, 14%), abnormal to partial response (Abnl-Cy to Partial-Cy, n = 20, 3.6%), and abnormal to complete response (Abnl-Cy to NL-Cy, n = 195, 35%). Landmark analysis was used to account for post-treatment assessments. The cohort had a median age of 62 years (interquartile range: 52-69), 256 females (45%), 90% were White, and median follow-up of 45.8 months (range: 0.73-191.3). The median OS and hazard ratios (HRs) from multivariable regression analysis were as follows: NL-Cy to NL-Cy: 37 months (95% CI: 27-91), HR = reference; NL/Abnl-Cy to Gain-Cy: 14 months (95% CI: 8.6-30), HR = 1.5 (95% CI: 0.99-2.39); Abnl-Cy to Persistent-Cy: 13 months (95% CI: 12-18), HR = 1.61 (95% CI: 1.13-2.31); Abnl-Cy to Partial-Cy: 25 months (95% CI: 14-NC), HR = 0.76 (95% CI: 0.39-1.49); and Abnl-Cy to NL-Cy: 27 months (95% CI: 19-101), HR = 1.25 (95% CI: 0.93-1.68) (p = 0.038). Achieving cytogenetic remission, complete or partial, was associated with better survival outcomes. These findings highlight the importance of monitoring cytogenetic responses to inform treatment decisions and support integrating cytogenetic response into risk-adapted, personalized AML management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.